Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06966700 · ClinicalTrials.gov registry record · Phase 3
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
A Phase 3 study of Breast Neoplasms and Triple Negative Breast Neoplasms, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 2,400
- Enrollment target
- 20
- Study locations
NCT06966700 is a Phase 3 study of Breast Neoplasms and Triple Negative Breast Neoplasms that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 2,400 participants, above the 544-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (341% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT06966700, a Phase 3 study of Breast Neoplasms and Triple Negative Breast Neoplasms, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,400 participants
- Enrollment target
- 20
- Study locations
Study Summary
Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in the breast or the lymph nodes around the breast The 2 types of breast cancer in this study are triple-negative breast cancer (TNBC) and hormone receptor (HR)-low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. These cancers have zero or a low amount of a protein called HER2 and other proteins that attach to the hormones estrogen or progesterone. Sacituzumab tirumotecan (also known as sac-TMT or MK-2870), the study medicine, is a type of targeted therapy. A targeted therapy is a treatment that works to control how specific types of cancer cells grow and spread. The main goals of this study are to learn if people who receive sac-TMT, pembrolizumab, and chemotherapy: * Have fewer cancer cells found in the tumors and lymph nodes removed during surgery compared to those who receive only pembrolizumab and chemotherapy * Live longer without the cancer growing, spreading, or coming back compared to people who receive only pembrolizumab with chemotherapy
Conditions Studied
Interventions
- BIOLOGICAL Sacituzumab tirumotecan
- BIOLOGICAL Pembrolizumab
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG Rescue Medication
Study Locations (20)
California
- Roy and Patricia Disney Family Cancer Center ( Site 0055) - Burbank
- Providence Medical Foundation ( Site 0080) - Fullerton
- Hoag Memorial Hospital Presbyterian ( Site 0010) - Newport Beach
- Helios Clinical Research ( Site 0061) - Whittier
Florida
- AdventHealth Medical Group Oncology and Hematology at Altamonte ( Site 0044) - Altamonte Springs
- Florida Cancer Specialists - South ( Site 7004) - Fort Myers
- Bioresearch Partner ( Site 0072) - Hialeah
- Florida Cancer Specialists - North ( Site 7002) - St. Petersburg
Arizona
- Banner MD Anderson Cancer Center ( Site 0066) - Gilbert
- University of Arizona Cancer Center ( Site 0035) - Tucson
Colorado
- Intermountain Health Cancer Center Saint Joseph ( Site 0062) - Denver
- Intermountain Health St. Mary's Regional Hospital ( Site 0054) - Grand Junction
Indiana
- Fort Wayne Medical Oncology and Hematology ( Site 0084) - Fort Wayne
- Franciscan Health ( Site 0077) - Indianapolis
Louisiana
- Ochsner Clinic Foundation ( Site 0021) - New Orleans
- Louisiana State University Health Sciences Shreveport ( Site 0053) - Shreveport
Missouri
- Saint Luke's Cancer Institute ( Site 0059) - Kansas City
- Washington University Siteman Cancer Center ( Site 0031) - St Louis
Maine
- New England Cancer Specialists ( Site 0051) - Westbrook
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,400 participants |
| Start Date | 2025-06-30 |
| Est. Completion | 2034-12-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06966700
The ClinicalTrials.gov registry entry for NCT06966700 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 2,400 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 544-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (341% higher). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Breast Neoplasms appearing as the primary indexed condition, and to 5 interventions - of which Sacituzumab tirumotecan is the first listed.
NCT06966700 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06966700 about?
NCT06966700 is a clinical study titled "A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)". Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in the breast or the lymph nodes around the breast The 2 types of...
What is the current status of trial NCT06966700?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 2,400 participants. The study started on 2025-06-30. Estimated completion is 2034-12-29.
What conditions does trial NCT06966700 study?
This clinical trial studies the following conditions: Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms.
What interventions are being tested in trial NCT06966700?
The interventions under investigation include: Sacituzumab tirumotecan (BIOLOGICAL), Pembrolizumab (BIOLOGICAL), Carboplatin (DRUG), Paclitaxel (DRUG), Rescue Medication (DRUG).
Who is sponsoring clinical trial NCT06966700?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06966700 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
RECRUITING · Phase 3
-
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
RECRUITING · Phase 3
-
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
RECRUITING · Phase 3
-
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
RECRUITING · Phase 3
-
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
RECRUITING · Phase 3
-
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.